The global etoposide market is expected to grow at a significant CAGR during the forecast period (2021-2027). Etoposide is a semisynthetic derivative of podophyllotoxin comprising epipodophyllotoxin. Etoposide acts on the S and G2 stages of the cell cycle and inhibits DNA topoisomerase II, thereby halting the process of DNA synthesis. The lysis of cells undergoing mitosis is found at high doses (10 g/mL or higher). Cells are prevented from entering prophase at low doses (0.3 to 10 g/mL). It does not affect the microtubule assembly. The most important effect of etoposide is the interference in the interaction of DNA topoisomerase II and breaking the production of DNA strands.

Etoposide prevents DNA re-ligation by blocking DNA topoisomerase II. This results in crucial mistakes in DNA synthesis during the premitotic stage of cell division, which can lead to cancer cell death. The cell cycle dependency and phase specificity of etoposide inhibit the alpha form of topoisomerase II producing an anti-tumour effect. The medication can also block the beta isoform, however, this target isn't linked to anti-tumour efficacy. Instead, it's linked to a carcinogenic impact.

Etoposide is marketed under the names Etopophos, Toposar, and Vepesid. Etopophos has the biggest revenue share in the entire etoposide market of all of them. The rising prevalence of lung cancer is one of the key factors driving the growth of the global etoposide market during the forecast period. In addition, the rising incidence of Ewing sarcoma will drive the global etoposide market growth.

The growing number of individuals living with acquired immune deficiency syndrome (AIDS) will drive the etoposide market growth, as persons with AIDS are at a higher risk of acquiring Kaposi's sarcoma. The growth of the global etoposide market will be driven by an increase in the number of patients suffering from stomach cancer. In March 2021, US FDA authorized Imfinzi from AstraZeneca for the treatment of advanced-stage small cell lung cancer in adults in combination with chemotherapies and platinum etoposide. The authorization was granted based on the positive results from the Phase III trials which showed Imfinzi to be effective in combination with platinum etoposide.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Type 

o By Application 

• Regions Covered

o North America

o Europe

o Asia-Pacific

o Rest of the world

• Competitive Landscape: Pharmedic Laboratories Pvt. Ltd, Teva Pharmaceutical Industries Ltd, Ben Venue Laboratories, and Accord Healthcare, Inc. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Etoposide Market by Segments

By Type

• Injectable
• Oral Use

By Application

• Small Cell Lung Cancer
• Testicular Cancer

Global Etoposide Market by Region